Amanda Przespolewski

DO
Medical Oncology

Specializing In:

Acute myeloid leukemia (AML) Acute lymphoblastic leukemia (ALL) Chronic myeloid leukemia (CML) Myeloproliferative diseases (MPD) Myelodysplastic syndrome (MDS) Hematologic Oncology

Special Interests:

Bone Marrow Microenvironment Immunotherapy Early Phase Clinical Trials Translational Medicine

About Amanda Przespolewski

Biography:

I joined the Leukemia Service within the Department of Medicine at Roswell Park in July 2017. I treat patients with both malignant and non-malignant blood disorders. This includes patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and myeloproliferative neoplasms. As a native of Buffalo, NY, I completed a large portion of my training locally. I received my doctoral degree in 2011 from the Lake Erie College of Osteopathic Medicine in Erie, PA. My residency in Internal Medicine and fellowship in Hematology and Medical Oncology were both completed through the University at Buffalo. I hold board certifications in Internal Medicine, Hematology and Medical Oncology.

My research interests include Early Phase Clinical Trials for high-risk myeloid malignancies, as well as translational medicine. My translational work is focused on understanding how leukemic blasts modulate the local immune system to evade detection, and therefore identifying new therapeutic targets.

Positions

Roswell Park Comprehensive Cancer Center

  • Assistant Professor
  • Department of Medicine

Jacobs School Of Medicine And Biomedical Sciences, State University of New York at Buffalo

  • Assistant Professor
  • Department of Medicine

Background

Education and Training:

  • 2011 - DO - Lake Erie College of Osteopathic Medicine, Erie, PA

Residency:

  • 2014 - Internal Medicine - University at Buffalo, Buffalo, NY

Fellowship:

  • 2017 - Hematology and Oncology - University at Buffalo, Buffalo, NY

Board Certification:

  • 2018 - Hematology
  • 2017 - Medical Oncology
  • 2016 - Internal Medicine

Professional Memberships:

  • American Society of Hematology
  • American Society of Clinical Oncology
  • American Association for Cancer Research
  • Society for Immunotherapy of Cancer

Professional Experience:

  • NCCN Acute Myeloid Leukemia Panel Member
  • NCCN Acute Lymphoblastic Leukemia Panel Member

Honors & Awards:

  • 2017 University at Buffalo Scholarly Exchange Day Research Award
  • 2017 Thomas F. Frawley Residency Research Fellowship
  • 2016 American Society of Hematology Abstract Award ASH Meeting on Hematologic Malignancies
  • 2015-2016 University at Buffalo GME Quality Improvement Award

Clinical Trials


Publications

Full Publications list on PubMed

Przespolewski A, Muppidi MR, Freyer CW, Ji W, Cronin TL, Thota S, Griffiths EA, Thompson JE, Ontiveros EP, Baron J, Elshoury A, Wang ES. Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy. Leuk Lymphoma. 2021 Feb 16:1-6. doi: 10.1080/10428194.2021.1885654. Epub ahead of print. PMID: 33593230.

Przespolewski AC, Griffiths EA. BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting. Blood Rev. 2020 Sep;43:100654. doi: 10.1016/j.blre.2020.100654. Epub 2020 Jan 21. PMID: 32029263; PMCID: PMC7371541.

Chen GL, Wallace PK, Zhang Y, Tario JD Jr, Przespolewski AC, Becker J, Almyroudis NG, Ross M, Riches M, Segal BH, Brix L, McCarthy PL, Hahn T. Low-Level Cytomegalovirus Antigenemia Promotes Protective Cytomegalovirus Antigen-Specific T Cells after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 Nov;26(11):2147-2154. doi: 10.1016/j.bbmt.2020.07.024. Epub 2020 Jul 25. PMID: 32721522; PMCID: PMC7609607.

Fritz C, Portwood SM, Przespolewski A, Wang ES. PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias. Blood Rev. 2021 Jan;45:100696. doi: 10.1016/j.blre.2020.100696. Epub 2020 May 7. PMID: 32482307.

Talati C, Goldberg AD, Przespolewski A, Chan O, Ali NA, Kim J, Famulare C, Sallman D, Padron E, Kuykendall A, Lancet JE, Wang E, Tallman MS, Komrokji R, Sweet K. Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leuk Res. 2020 Jun;93:106367. doi: 10.1016/j.leukres.2020.106367. Epub 2020 May 1. PMID: 32408060; PMCID: PMC7771257.